EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):
2013 ◽
Vol 14
(12)
◽
pp. 24549-24559
◽
Keyword(s):
2014 ◽
Vol 9
(2)
◽
pp. 189-194
◽
Keyword(s):
Keyword(s):